Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder

Olsson SK, Sellgren C, Engberg G, Landén M, Erhardt S. Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder. Bipolar Disord 2012: 14: 719–726. © 2012 The Authors. Journal compilation © 2012 John Wiley & Sons A/S.

[1]  M. Holtze,et al.  Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. , 2012, Schizophrenia bulletin.

[2]  S. Erhardt,et al.  Subchronic elevation of brain kynurenic acid augments amphetamine-induced locomotor response in mice , 2012, Journal of Neural Transmission.

[3]  R. Schwarcz,et al.  Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. , 2011, Schizophrenia bulletin.

[4]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[5]  M. Landén,et al.  Elevation of cerebrospinal fluid interleukin-1ß in bipolar disorder. , 2011, Journal of psychiatry & neuroscience : JPN.

[6]  M. Ingvar,et al.  Manic episodes are associated with grey matter volume reduction — a voxel‐based morphometry brain analysis , 2010, Acta psychiatrica Scandinavica.

[7]  S. Powell,et al.  Neonatal infection with neurotropic influenza A virus induces the kynurenine pathway in early life and disrupts sensorimotor gating in adult Tap1-/- mice. , 2010, The international journal of neuropsychopharmacology.

[8]  E. Jönsson,et al.  Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. , 2010, Journal of psychiatry & neuroscience : JPN.

[9]  R. Schwarcz,et al.  Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. , 2010, Schizophrenia bulletin.

[10]  S. Rossell,et al.  Gender differences in prepulse inhibition (PPI) in bipolar disorder: men have reduced PPI, women have increased PPI. , 2009, The international journal of neuropsychopharmacology.

[11]  D. Bucci,et al.  L-kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning , 2009, Behavioural Brain Research.

[12]  K N Roy Chengappa,et al.  Identifying and treating cognitive impairment in bipolar disorder. , 2009, Bipolar disorders.

[13]  K. Larsson,et al.  Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. , 2009, The international journal of neuropsychopharmacology.

[14]  A. Carlsson,et al.  EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. , 2009, Acta pharmacologica et toxicologica.

[15]  M. Holtze,et al.  Induction of the kynurenine pathway by neurotropic influenza a virus infection , 2008, Journal of neuroscience research.

[16]  S. Erhardt,et al.  Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area. , 2008, Life sciences.

[17]  J. Meador-Woodruff,et al.  Lamina-Specific Abnormalities of NMDA Receptor-Associated Postsynaptic Protein Transcripts in the Prefrontal Cortex in Schizophrenia and Bipolar Disorder , 2008, Neuropsychopharmacology.

[18]  S. Erhardt,et al.  Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: A pharmacological analysis , 2007, Neuropharmacology.

[19]  Gilles J Guillemin,et al.  Characterization of the Kynurenine Pathway in Human Neurons , 2007, The Journal of Neuroscience.

[20]  D. Bucci,et al.  Elevations of endogenous kynurenic acid produce spatial working memory deficits. , 2007, Schizophrenia bulletin.

[21]  R. Panizzutti,et al.  A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia , 2007, Schizophrenia Research.

[22]  W. Turski,et al.  Enhancement of brain kynurenic acid production by anticonvulsants--novel mechanism of antiepileptic activity? , 2006, European journal of pharmacology.

[23]  D. Bucci,et al.  Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding , 2006, Behavioural Brain Research.

[24]  S. Erhardt,et al.  Subchronic treatment with kynurenine and probenecid: effects on prepulse inhibition and firing of midbrain dopamine neurons , 2006, Journal of Neural Transmission.

[25]  S. Erhardt,et al.  Effects of COX‐1 and COX‐2 inhibitors on the firing of rat midbrain dopaminergic neurons—Possible involvement of endogenous kynurenic acid , 2006, Synapse.

[26]  S. Weis,et al.  Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder , 2006, Brain Research.

[27]  R. Schwarcz,et al.  Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain , 2006, Journal of Neural Transmission.

[28]  K. Blennow,et al.  Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia , 2005, Schizophrenia Research.

[29]  M. Geyer,et al.  Endogenous kynurenic acid disrupts prepulse inhibition , 2004, Biological Psychiatry.

[30]  D. Kupfer,et al.  Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD) , 2003, Biological Psychiatry.

[31]  L. Clerkin,et al.  Micromolar Brain Levels of Kynurenic Acid are Associated with a Disruption of Auditory Sensory Gating in the Rat , 2003, Neuropsychopharmacology.

[32]  S. Erhardt,et al.  Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid. , 2002, Acta physiologica Scandinavica.

[33]  K. Blennow,et al.  Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia , 2001, Neuroscience Letters.

[34]  R. Schwarcz,et al.  Increased cortical kynurenate content in schizophrenia , 2001, Biological Psychiatry.

[35]  R. Schwarcz,et al.  The Brain Metabolite Kynurenic Acid Inhibits α7 Nicotinic Receptor Activity and Increases Non-α7 Nicotinic Receptor Expression: Physiopathological Implications , 2001, The Journal of Neuroscience.

[36]  John E. Cooper,et al.  Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision) (DSM-IV-TR) , 2001 .

[37]  M. Laruelle,et al.  Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia , 2000, Biological Psychiatry.

[38]  J. Seibyl,et al.  Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. , 2000, The American journal of psychiatry.

[39]  A. Malhotra,et al.  Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. , 1999, The American journal of psychiatry.

[40]  R. Roth,et al.  The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia , 1999, Neuropsychopharmacology.

[41]  J. Krystal,et al.  Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. , 1998, The American journal of psychiatry.

[42]  C. Parsons,et al.  Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. , 1997, The Journal of pharmacology and experimental therapeutics.

[43]  Anil K Malhotra,et al.  Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics , 1997, Neuropsychopharmacology.

[44]  A. Malhotra,et al.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Krystal,et al.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[46]  R. Schwarcz,et al.  Immunocytochemical localization of kynurenine aminotransferase in the rat striatum: A light and electron microscopic study , 1992, The Journal of comparative neurology.

[47]  M. Beal,et al.  Measurement of kynurenic acid in mammalian brain extracts and cerebrospinal fluid by high-performance liquid chromatography with fluorometric and coulometric electrode array detection. , 1990, Analytical biochemistry.

[48]  G. Lynch,et al.  A Glycine Site Associated with N‐Methyl‐d‐Aspartic Acid Receptors: Characterization and Identification of a New Class of Antagonists , 1989, Journal of neurochemistry.

[49]  C. Grossman,et al.  Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. , 1988, European journal of pharmacology.

[50]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[51]  R. C. Young,et al.  A Rating Scale for Mania: Reliability, Validity and Sensitivity , 1978, British Journal of Psychiatry.

[52]  D. Murphy,et al.  Regular Induction of Hypomania by L-Dopa in “Bipolar” Manic-depressive Patients , 1971, Nature.

[53]  R. Dantzer,et al.  From inflammation to sickness and depression: when the immune system subjugates the brain , 2008, Nature Reviews Neuroscience.

[54]  E. Jönsson,et al.  Cerebrospinal fluid kynurenic acid in male and female controls - correlation with monoamine metabolites and influences of confounding factors. , 2007, Journal of psychiatric research.

[55]  N. King,et al.  Molecules in focus: indoleamine 2,3-dioxygenase. , 2007, The international journal of biochemistry & cell biology.

[56]  B. Kepplinger,et al.  Age-related increase of kynurenic acid in human cerebrospinal fluid - IgG and beta2-microglobulin changes. , 2005, Neuro-Signals.

[57]  R. Schwarcz,et al.  Kynurenate production by cultured human astrocytes , 2003, Journal of Neural Transmission.

[58]  R. Schwarcz,et al.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[59]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[60]  A. Ganong,et al.  Kynurenic acid and quinolinic acid act at N-methyl-D-aspartate receptors in the rat hippocampus. , 1986, The Journal of pharmacology and experimental therapeutics.

[61]  H. Wright,et al.  Phencyclidine-induced psychosis. , 1980, Southern medical journal.